Anti‐tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region

Abstract

Although anti-tumor necrosis factor (TNF) agents have greatly improved the management of rheumatic diseases, their cost limits access to many patients throughout the world. As a result, patients and clinicians have turned to biosimilars to provide similar efficacy at a lower cost. Many of the regulatory guidelines in the Asia Pacific region are largely based on those of the European Medicines Agency and the World Health Organization; however, there are variations between countries. Additionally, in some countries, intended copies are available that were approved prior to the development of guidelines and have not fulfilled the requirements of a biosimilar.We review the various regulatory requirements for biosimilars in the Asia Pacific region, the anti-TNF biosimilars and intended copies approved in the region, and whether clinical data are available for these agents. We discuss concerns about the need for additional regulations and education, and we provide recommendations for a multidisciplinary pharmacovigilance approach that closely monitors the safety of biosimilar use.

Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review

“…Regulatory reliance was reported in other areas of pharmaceutical policy. LMIC regulators reportedly use an iteration of the EMA guidelines for evaluating biosimilar products as a model for standards adopted in China [48] , Malaysia [48] , South Africa [49] , and Ukraine [ 49 , 50 ]. LMIC regulators may also draw from the EMA's post-marketing updates to market authorisations.…”

Glyceroglycolipids in marine algae: A review of their pharmacological activity

“…Currently, the main methods to treat tumors are surgery, radiotherapy, chemotherapy, and hormone therapy (Zhang W. et al, 2020). Although these methods can have certain therapeutic effects, in many cases, they also have serious adverse events (Rath et al, 2019;Yan et al, 2019). Therefore, research on more effective oncology drugs with lesser toxicity is of great significance and has become a research hotspot.…”

A Randomized, Double‐Blind, Parallel‐Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects

“…7 Although biologics (etanercept, adalimumab, tocilizumab, infliximab) have shown significant improvements in efficacy and safety, the real-world use of biological agents in China is lower due to their high cost and medical insurance reimbursement issues. 8 As the expiration date of the patented originator adalimumab nears, physicians expect a biosimilar to have comparable properties with regard to safety, immunogenicity, and efficacy. Ideally, the biosimilar should be marketed at a lower price.…”